A leading investment expert says ASX investors have a rare chance to buy CSL shares at a discount. CSL shares remain down 35.2% over the past year, impacted by concerns over vaccine sales and ...
Hosted on MSN
E46 M3 CSL Dyno Test Power Run
We put our E46 M3 CSL on the dyno to find out exactly how much power it’s making after years on the road. Known for its lightweight design and legendary S54 engine, the CSL is a special car — but how ...
Some of Australia’s largest blue-chip investors have been caught on the wrong side of one of the year’s most crowded trades after piling into CSL as an alternative to holding a big position in ...
SYDNEY--Australia-based pharmaceutical company CSL plans to expand its U.S. production over the next five years as part of a $1.5 billion investment in the country. CSL, which produces plasma-derived ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The company announced in August ...
Health editor Michael Smith on CSL’s remarkable story, why investors have fallen out of love with the healthcare giant and what Trump has to do with it. CSL was run like a bureaucracy until 1990 when ...
CSL Ltd., the world’s second-biggest maker of flu shots, forecast a US vaccination rebound as health groups counter misinformation and rising illness rates revive concern about prevention. A recovery ...
US vaccination forecast leads to fall in stock price, while board survives spill in ‘second strike’ over pay concerns at AGM Follow our Australia news live blog for latest updates Get our breaking ...
Good morning, ladies and gentlemen. We still have some people registering, but we always start our Board meetings on time at CSL. So today will be no exception. Welcome to CSL's 2025 Annual General ...
SYDNEY, Oct 28 (Reuters) - Australian biotech CSL (CSL.AX), opens new tab has cut its profit outlook and delayed plans to spin off its vaccine division, blaming an unprecedented fall in U.S. flu ...
A strike is when more than 25 per cent of shareholders are against a company proposal, in this case executive pay, paving the way for a second ballot on whether to spill the board. Shareholders have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback